Rational Substitution of ε-Lysine for α-Lysine Enhances the Cell and Membrane Selectivity of Pore-Forming Melittin
Authors:
- 16 March 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (7) , 3522-3537
Abstract
Here we present a rational approach that enhances the membrane selectivity of a prolific pore-forming peptide, melittin, based on experimental observations that the cationic polymer, ε-polylysine, disrupts bacterial membrane with greater affinity over mammalian cells when compared to poly-L-lysine and poly-D-lysine. We systematically replaced 3 α-lysine residues in melittin with ε-lysine residues and identified key residues that are important for cytotoxicity. We then assessed the antimicrobial properties of modified peptides which carry 2 or 3 ε-lysyl residues. Two modified melittin peptides displayed rapid bactericidal properties against antibiotic-resistant strains, low innate resistance development by pathogenic bacteria, remained non-immunogenic for T-cell lymphocytes, and increased bioavailability in tear fluid. In proof-of-concept in vivo experiments, one of the peptides was non-cytotoxic for ocular surfaces and had comparable antimicrobial efficacy to that of fluoroquinolone antibiotics. The results uncover a simple and potential strategy that can enhance the membrane selectivity of cytolytic peptides by ε-lysylation.Keywords
Funding Information
- SingHealth Foundation (SHF/FG663P/2017)
- Agency for Science, Technology and Research (H17/01/a0/0K9)
- National Medical Research Council ((INCEPTOR)-NMRC/CG/M010/2017_SERI)
- Strategic Academic Initiative (L0494003)
- Lee Kong Chian School of Medicine, Nanyang Technological University Singapore (L0412290)
This publication has 61 references indexed in Scilit:
- Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals?International Journal of Antimicrobial Agents, 2011
- Investigation of the Potential for Mutational Resistance to XF-73, Retapamulin, Mupirocin, Fusidic Acid, Daptomycin, and Vancomycin in Methicillin-Resistant Staphylococcus aureus Isolates during a 55-Passage StudyAntimicrobial Agents and Chemotherapy, 2011
- Multiresistant Gram-negative infections: a global perspectiveCurrent Opinion in Infectious Diseases, 2010
- Management of multidrug-resistant enterococcal infectionsClinical Microbiology and Infection, 2010
- The 10 × ‘20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020Clinical Infectious Diseases, 2010
- Antibiotic-Resistant Bugs in the 21st Century — A Clinical Super-ChallengeNew England Journal of Medicine, 2009
- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- On the Mechanism of Pore Formation by MelittinJournal of Biological Chemistry, 2008
- Peptide Antimicrobial AgentsClinical Microbiology Reviews, 2006
- Antimicrobial peptides of multicellular organismsNature, 2002